Weiss Ratings Reiterates Sell (D-) Rating for OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “sell (d-)” rating restated by Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

OKYO has been the topic of a number of other research reports. Wall Street Zen raised OKYO Pharma to a “hold” rating in a research report on Saturday, August 9th. Zacks Research raised OKYO Pharma to a “hold” rating in a research report on Tuesday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Tuesday, September 23rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.00.

OKYO Pharma Stock Up 6.7%

OKYO Pharma stock opened at $2.39 on Friday. OKYO Pharma has a twelve month low of $0.90 and a twelve month high of $3.35. The stock’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $2.16.

Hedge Funds Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the company’s stock, valued at approximately $28,000. 2.97% of the stock is currently owned by institutional investors.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.